At first glance, the Johnson & Johnson Covid-19 vaccine looks to be the inferior option compared to the other approved options from Pfizer-BioNTech and Moderna, both of which reported around 95 percent effectiveness in their Phase 3 clinical trials. But Johnson & Johnson's single-dose shot, which has 72 percent effectiveness, isn't necessarily inferior. Here's why. |
No comments:
Post a Comment